SOLTI Breast Cancer Research Group
SOLTI Breast Cancer Research Group
Explore linked clinical trials.20 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-10-07 | NCT05512364 | |
| Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 | 2026-07-24 | NCT06078384 | |
| Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. | ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer; a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status | Active, not recruiting | Phase 2 | 2026-07-24 | NCT04053322 | |
| A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-07-06 | NCT06764186 | |
| Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-05-26 | NCT07237256 | |
| Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-05-14 | NCT05296746 | |
| Adjuvant Palbociclib in Elderly Patients With Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-05-12 | NCT03609047 | |
| Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-04-24 | NCT05982093 | |
| Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-03-27 | NCT07371585 | |
| Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Not applicable | 2026-02-20 | NCT06446882 | |
| Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, estrogen-receptor positive breast cancer, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-02-12 | NCT02947685 | |
| Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2025-09-09 | NCT04759248 | |
| HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a) | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, metastatic malignant neoplasm, neoplasm | Active, not recruiting | Not applicable | 2025-09-09 | NCT04257162 | |
| Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102) | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, metastatic prostate carcinoma, neoplasm, prostate cancer, prostate disorder | Recruiting | Not stated | 2025-08-06 | NCT05885009 | |
| Real World Study Using Comprehensive Genomic Data on the Next Treatment Decision Making in Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Not stated | 2025-08-06 | NCT04497285 | |
| Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic Breast Cancer in Spain | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Not stated | 2025-05-28 | NCT06991946 | |
| Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors | Adnexal Diseases, Carcinoma, Ovarian Epithelial, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Liver Neoplasms, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplasms, Unknown Primary, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, Uveal Neoplasms, adenocarcinoma, adenoma, anal carcinoma, anus disorder, anus neoplasm, benign urinary system neoplasm, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cervical carcinoma, cervix disorder, cholangiocarcinoma, clear cell renal carcinoma, colorectal adenocarcinoma, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, esophageal adenocarcinoma, eye disorder, female reproductive system disorder, female reproductive system neoplasm, gastric adenocarcinoma, gonadal disorder, head and neck squamous cell carcinoma, hepatocellular carcinoma, intestinal disorder, kidney cancer, kidney disorder, liver disorder, lung adenocarcinoma, lung disorder, lung neoplasm, malignant endocrine neoplasm, melanocytic neoplasm, melanoma, mesothelial neoplasm, mesothelioma, neoplasm, neuroendocrine neoplasm, ocular cancer, ovarian cancer, ovarian disorder, pancreatic adenocarcinoma, primitive neuroectodermal tumor, prostate adenocarcinoma, rectal disorder, rectal neoplasm, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, sarcoma, skin disorder, skin neoplasm, small cell lung carcinoma, squamous cell carcinoma, squamous cell lung carcinoma, thyroid gland carcinoma, thyroid gland disorder, thyroid tumor, transitional cell carcinoma, triple-negative breast carcinoma, urinary system disorder, urothelial carcinoma, uterine carcinosarcoma, uterine disorder, uveal disorder, uveal melanoma | Active, not recruiting | Phase 2 | 2025-03-21 | NCT04802876 | |
| HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2024-07-19 | NCT06236269 | |
| Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS | Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 1 / Phase 2 | 2023-11-24 | NCT05451784 | |
| NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2023-09-21 | NCT05569811 |